You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR ATACAND HCT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Atacand Hct

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00150631 ↗ Danish Hypertension Prevention Project - DHYPP Unknown status AstraZeneca Phase 3 2000-11-01 The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
NCT00150631 ↗ Danish Hypertension Prevention Project - DHYPP Unknown status University of Aarhus Phase 3 2000-11-01 The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
NCT00150631 ↗ Danish Hypertension Prevention Project - DHYPP Unknown status Karin Skov Phase 3 2000-11-01 The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
NCT00227318 ↗ TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial Completed AstraZeneca Phase 3 1998-07-01 The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesartan or placebo for an initial 2-year period followed by a second 2-year period of placebo for all patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atacand Hct

Condition Name

Condition Name for Atacand Hct
Intervention Trials
Hypertension 18
Congestive Heart Failure 4
Type 1 Diabetes 3
Heart Failure 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atacand Hct
Intervention Trials
Hypertension 18
Heart Failure 7
Cognition Disorders 3
Retinal Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atacand Hct

Trials by Country

Trials by Country for Atacand Hct
Location Trials
United States 68
France 40
Korea, Republic of 17
Canada 8
Denmark 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atacand Hct
Location Trials
Texas 6
California 5
Tennessee 3
Pennsylvania 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atacand Hct

Clinical Trial Phase

Clinical Trial Phase for Atacand Hct
Clinical Trial Phase Trials
Phase 4 11
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atacand Hct
Clinical Trial Phase Trials
Completed 34
Unknown status 6
Terminated 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atacand Hct

Sponsor Name

Sponsor Name for Atacand Hct
Sponsor Trials
AstraZeneca 24
Takeda 5
GlaxoSmithKline 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atacand Hct
Sponsor Trials
Industry 36
Other 31
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for ATACAND HCT

Introduction

ATACAND HCT, a combination of candesartan cilexetil (ATACAND) and hydrochlorothiazide (HCT), is a widely used antihypertensive medication. This article delves into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Antihypertensive Efficacy and Safety

Several clinical trials have been conducted to evaluate the efficacy and safety of ATACAND HCT. One notable study is a double-blind, randomized, 4-arm parallel group, multicentre, 8-week, Phase III trial. This study compared the blood pressure lowering effects of the combination of candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg with candesartan cilexetil 32 mg, hydrochlorothiazide 25 mg, and placebo in hypertensive adults[1].

Dosage Variations

Another study focused on comparing the blood pressure lowering effects of different dosages of the combination, specifically candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg versus candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg, as well as candesartan cilexetil monotherapy[4].

Efficacy and Safety Findings

Blood Pressure Reduction

The combination of candesartan cilexetil and hydrochlorothiazide has been shown to be highly effective in reducing blood pressure. Studies indicate that the combination therapy offers superior blood pressure control compared to monotherapy with either component[1][4].

Safety Profile

The safety profile of ATACAND HCT has been evaluated in these trials, and it is generally well-tolerated. Common side effects are similar to those of the individual components, with no significant increase in adverse events when used in combination[1].

Market Analysis

Global Market Size and Growth

The global market for candesartan and hydrochlorothiazide is projected to witness significant growth. The market size is estimated to increase from 2019 to 2031, with the 16/12.5 mg segment accounting for a noticeable share and expected to experience significant growth in the near future[2].

Regional Analysis

The market is segmented into major regions including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific region is expected to dominate the market due to its growing pharmaceutical industry, favorable government policies, and cost benefits for clinical trials[2].

Key Players

Major pharmaceutical companies such as AstraZeneca and TEVA are focusing on strengthening their product portfolios and expanding their business in the global market. These companies are key players in the candesartan and hydrochlorothiazide market, driving growth through strategic initiatives[2].

Market Trends and Drivers

Increasing Demand for Antihypertensive Medications

The high prevalence of hypertension and cardiovascular diseases globally drives the demand for effective antihypertensive medications. This trend is expected to continue, fueling the growth of the ATACAND HCT market[5].

Regulatory and Cost Factors

Favorable regulatory environments and cost benefits, particularly in the Asia Pacific region, are significant drivers for the market. The low cost of clinical trials and manufacturing in this region attracts pharmaceutical and biopharmaceutical companies, contributing to market growth[5].

Future Projections

Market Growth Rate

The global candesartan and hydrochlorothiazide market is projected to grow at a significant CAGR from 2025 to 2031. The adult segment is expected to expand at a significant rate, retaining its position throughout the forecast period[2].

Segment Analysis

The 16/12.5 mg segment is anticipated to experience significant growth, while the 32/25 mg segment will also remain a key player in the market. The market analysis helps in understanding the key industry segments and their global, regional, and country-level insights[2].

Competitive Landscape

Strategic Initiatives

Companies like AstraZeneca and TEVA are focusing on building their strategy models to strengthen their product portfolios. This includes expanding their business in the global market through various strategic initiatives such as partnerships and investments in R&D[2].

Conclusion

ATACAND HCT is a crucial medication in the management of hypertension, backed by robust clinical trials and a strong market presence. The combination of candesartan cilexetil and hydrochlorothiazide offers effective blood pressure control with a favorable safety profile.

Key Takeaways

  • Clinical Efficacy: ATACAND HCT has been shown to be highly effective in reducing blood pressure in clinical trials.
  • Market Growth: The global market for candesartan and hydrochlorothiazide is projected to grow significantly from 2025 to 2031.
  • Regional Dominance: The Asia Pacific region is expected to dominate the market due to favorable regulatory environments and cost benefits.
  • Competitive Landscape: Major pharmaceutical companies are driving market growth through strategic initiatives and investments in R&D.

FAQs

What is the primary purpose of the clinical trials for ATACAND HCT?

The primary purpose of these trials is to assess the antihypertensive efficacy and safety of the combination of candesartan cilexetil and hydrochlorothiazide compared to monotherapy and placebo.

Which regions are expected to drive the growth of the ATACAND HCT market?

The Asia Pacific region is expected to dominate the market due to its growing pharmaceutical industry, favorable government policies, and cost benefits for clinical trials.

What are the key segments driving the growth of the candesartan and hydrochlorothiazide market?

The 16/12.5 mg and 32/25 mg segments are anticipated to experience significant growth, with the adult segment expanding at a significant CAGR.

Who are the major players in the candesartan and hydrochlorothiazide market?

Major pharmaceutical companies such as AstraZeneca and TEVA are key players, driving growth through strategic initiatives and investments in R&D.

What are the main drivers for the growth of the ATACAND HCT market?

The high prevalence of hypertension, favorable regulatory environments, and cost benefits, particularly in the Asia Pacific region, are significant drivers for the market.

Sources

  1. AstraZeneca Clinical Trials: Antihypertensive efficacy and safety of Candesartan/HCT 32/25 mg.
  2. Cognitive Market Research: Global Candesartan and Hydrochlorothiazide Market Report 2024.
  3. Exploration Pub: Current therapeutics for Alzheimer's disease and clinical trials.
  4. AstraZeneca Clinical Trials: Antihypertensive efficacy and safety of Candesartan/HCT 32/12.5 mg.
  5. MarketsandMarkets: Clinical Trials Market Size, Share, Trends and Revenue Forecast.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.